Women’s cardiovascular health – the cardio-oncologic jigsaw

References

• Health AIo W. Cardiovascular disease in women. Canberra: AIHW; 2019.
   Google Scholar
• Keteepe-Arachi T, Sharma S, et al. Cardiovascular disease in women: understanding symptoms and risk factors. Eur Cardiol Rev. 2017;12(1):10–13. doi: 10.15420/ecr.2016:32:1.
   PubMedGoogle Scholar
• Aggarwal NR, Patel HN, Mehta LS, et al. Sex differences in ischemic heart disease: Advances, obstacles, and next steps. Circ Cardiovasc Qual Outcomes. 2018;11(2):e004437.
   PubMed Web of Science ®Google Scholar
• Statistics A. Causes of death, Australia. Canberra: ABS. 2021.
   Google Scholar
• Khan E, Brieger D, Amerena J, et al. Differences in management and outcomes for men and women with ST‐elevation myocardial infarction. Med J Austr. 2018;209(3):118–123. doi: 10.5694/mja17.01109.
   PubMed Web of Science ®Google Scholar
• Health AIo W. Cancer in Australia 2021. Canberra: AIHW; 2021.
   Google Scholar
• Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736–1788. doi: 10.1016/S0140-6736(18)32203-7.
   PubMed Web of Science ®Google Scholar
• Moslehi J, Lenihan DJ. Cardio-oncology: time to get more mechanistic. Washington (DC): American College of Cardiology Foundation; 2017. p. 54–55.
   Google Scholar
• Ye Y, Otahal P, Marwick TH, et al. Cardiovascular and other competing causes of death among patients with cancer from 2006 to 2015: an Australian population‐based study. Cancer. 2019;125(3):442–452. doi: 10.1002/cncr.31806.
   PubMed Web of Science ®Google Scholar
• Aboumsallem JP, Moslehi J, de Boer RA. Reverse cardio‐oncology: cancer development in patients with cardiovascular disease. JAHA. 2020;9(2):e013754. doi: 10.1161/JAHA.119.013754.
   Google Scholar
• Williams TD, Kaur A, Warner T, et al. Cardiovascular outcomes of cancer patients in rural Australia. Front Cardiovasc Med. 2023;10:1144240. doi: 10.3389/fcvm.2023.1144240.
   PubMedGoogle Scholar
• Sverdlov AL, Koczwara B, Cehic DA, et al. When cancer and cardiovascular disease intersect: the challenge and the opportunity of cardio-oncology. Heart Lung Circ. 2023 Jun 13:S1443–9506(23)00510-3. doi: 10.1016/j.hlc.2023.04.301. Epub ahead of print.
   Google Scholar
• Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280–299. doi: 10.1093/eurheartj/ehab674.
   PubMed Web of Science ®Google Scholar
• Lee GA, Aktaa S, Baker E, et al. European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment. Eur Heart J Qual Care Clin Outcomes. 2022;9(1):1–7. doi: 10.1093/ehjqcco/qcac070.
   PubMed Web of Science ®Google Scholar
• Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022;43(41):4229–4361. doi: 10.1093/eurheartj/ehac244.
   PubMed Web of Science ®Google Scholar
• Papageorgiou C, Andrikopoulou A, Dimopoulos MA, et al. Cardiovascular toxicity of breast cancer treatment: an update. Cancer Chemother Pharmacol. 2021;88(1):15–24. doi: 10.1007/s00280-021-04254-w.
   PubMed Web of Science ®Google Scholar
• Parashar S, Akhter N, Paplomata E, et al. Cancer treatment-related cardiovascular toxicity in gynecologic malignancies. JACC. 2023;5(2):159–173. doi: 10.1016/j.jaccao.2023.02.002.
   Google Scholar
• Lee Chuy K, Yu AF. Cardiotoxicity of contemporary breast cancer treatments. Curr Treat Options Oncol. 2019;20(6):51.
   PubMed Web of Science ®Google Scholar
• Galimzhanov A, Istanbuly S, Tun HN, et al. Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis. Eur J Prev Cardiol. 2023 Jul 27:zwad243. doi: 10.1093/eurjpc/zwad243. Epub ahead of print.
   Web of Science ®Google Scholar
• Lefrak EA, Piťha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32(2):302–314. doi: 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2.
   PubMed Web of Science ®Google Scholar
• Sawicki KT, Sala V, Prever L, et al. Preventing and treating anthracycline cardiotoxicity: new insights. Annu Rev Pharmacol Toxicol. 2021;61(1):309–332. doi: 10.1146/annurev-pharmtox-030620-104842.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA A Cancer J Clin. 2021;71(1):7–33. doi: 10.3322/caac.21654.
   PubMed Web of Science ®Google Scholar
• Okwuosa TM, Zaha VG. Sex differences in cardio-oncology: considerations for the practicing clinician and researcher. Circulation. 2022;145(7):510–512. doi: 10.1161/CIRCULATIONAHA.122.058906.
   PubMed Web of Science ®Google Scholar
• Omland T, Heck SL, Gulati G. The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2022;4(1):19–37.
   PubMedGoogle Scholar
• Lin M, Xiong W, Wang S, et al. The research progress of trastuzumab-induced cardiotoxicity in HER-2-positive breast cancer treatment. Front Cardiovasc Med. 2022;8:2075. doi: 10.3389/fcvm.2021.821663.
   Web of Science ®Google Scholar
• Chen D, Kelly C, Haw TJ, et al. Heart failure in breast cancer survivors: focus on early detection and novel biomarkers. Curr Heart Fail Rep. 2021;18(6):362–377. doi: 10.1007/s11897-021-00535-w.
   PubMed Web of Science ®Google Scholar
• van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1630–1640. doi: 10.1016/S1470-2045(18)30570-9.
   PubMed Web of Science ®Google Scholar
• Chang W-T, Chen P-W, Lin H-W, et al. Risks of aromatase inhibitor-related cardiotoxicity in patients with breast cancer in Asia. Cancers. 2022;14(3):508. doi: 10.3390/cancers14030508.
   PubMed Web of Science ®Google Scholar
• Matthews AA, Hinton SP, Stanway S, et al. Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors. Heart. 2021;107(16):1327–1335. doi: 10.1136/heartjnl-2020-317510.
   PubMed Web of Science ®Google Scholar
• Goldvaser H, Barnes TA, Šeruga B, et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2018;110(1):31–39. doi: 10.1093/jnci/djx141.
   Google Scholar
• Kassaian SE, Gandhi B, Barac A. Cardio-oncology: implications for clinical practice for women. Curr Cardiol Rep. 2022;24(11):1685–1698. doi: 10.1007/s11886-022-01779-1.
   PubMed Web of Science ®Google Scholar
• Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579–1589. doi: 10.1016/S1470-2045(18)30608-9.
   PubMed Web of Science ®Google Scholar
• Canale ML, Bisceglia I, Gallucci G, et al. Women at heart: introducing gender cardio-oncology. Front Cardiovasc Med. 2022;9:974123. doi: 10.3389/fcvm.2022.974123.
   PubMed Web of Science ®Google Scholar
• Russo G, Rea F, Barbati G, et al. Sex-related differences in chronic heart failure: a community-based study. J Cardiovasc Med. 2021;22(1):36–44. doi: 10.2459/JCM.0000000000001049.
   Google Scholar
• Matta A, Delmas C, Campelo-Parada F, et al. Takotsubo cardiomyopathy. Rev Cardiovasc Med. 2022;23(1):1. doi: 10.31083/j.rcm2301038.
   PubMed Web of Science ®Google Scholar
• Boekhout AH, Beijnen JH, Schellens JH. Symptoms and treatment in cancer therapy-induced early menopause. Oncologist. 2006;11(6):641–654. doi: 10.1634/theoncologist.11-6-641.
   PubMed Web of Science ®Google Scholar
• Zhu D, Chung HF, Dobson AJ, et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health. 2019 Nov;4(11):e553-e564. doi: 10.1016/S2468-2667(19)30155-0. Epub ahead of print.
   Google Scholar
• Vincent A. Management of menopause in women with breast cancer. Climacteric. 2015;18(5):690–701. doi: 10.3109/13697137.2014.996749.
   PubMed Web of Science ®Google Scholar
• Gong IY, Tan NS, Ali SH, et al. Temporal trends of women enrollment in major cardiovascular randomized clinical trials. Canad J Cardiol. 2019;35(5):653–660. doi: 10.1016/j.cjca.2019.01.010.
   PubMed Web of Science ®Google Scholar
• Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive ­cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio‐Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International ­Cardio‐Oncology Society. Eur J Heart Fail. 2020;22(11):1945–1960. doi: 10.1002/ejhf.1920.
   PubMed Web of Science ®Google Scholar
• Nolan MT, Creati L, Koczwara B, et al. First European Society of Cardiology Cardio-Oncology Guidelines: a big leap forward for an emerging specialty. Heart Lung Circ. 2022;31(12):1563–1567. doi: 10.1016/j.hlc.2022.11.003.
   PubMed Web of Science ®Google Scholar
• Battisti NML, Andres MS, Lee KA, et al. Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. Breast Cancer Res Treat. 2021;188(1):149–163. doi: 10.1007/s10549-021-06192-w.
   PubMed Web of Science ®Google Scholar
• Health AIo W. Women and heart disease: cardiovascular profile of women in Australia. Canberra: AIHW; 2010.
   Google Scholar
• López-Fernandez T, Dent SF. Strategies for risk stratification and cardiovascular toxicity prevention in patients with cancer. Dent. 2023;2(:1–22.
   Google Scholar
• Muhandiramge J, Zalcberg JR, van Londen G, et al. Cardiovascular disease in adult cancer survivors: a review of current evidence, strategies for prevention and management, and future directions for cardio-oncology. Curr Oncol Rep. 2022;24(11):1579–1592. doi: 10.1007/s11912-022-01309-w.
   PubMed Web of Science ®Google Scholar
• Strongman H, Gadd S, Matthews A, et al. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. The Lancet. 2019;394(10203):1041–1054. doi: 10.1016/S0140-6736(19)31674-5.
   PubMed Web of Science ®Google Scholar
• Untaru R, Chen D, Kelly C, et al. Suboptimal use of cardioprotective medications in patients with a history of cancer. Cardio Oncol. 2020;2(2):312–315. doi: 10.1016/j.jaccao.2020.05.010.
   PubMedGoogle Scholar
• Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018;104(12):971–977.
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–1672. doi: 10.1056/NEJMoa052306.
   PubMed Web of Science ®Google Scholar
• Neilan TG, Quinaglia T, Onoue T, et al. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial. JAMA. 2023 Aug 8;330(6):528–536. doi: 10.1001/jama.2023.11887.
   Google Scholar
• Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22):2749–2754. doi: 10.1161/01.CIR.0000130926.51766.CC.
   PubMed Web of Science ®Google Scholar
• Ananthan K, Lyon AR. The role of biomarkers in cardio-oncology. J Cardiovasc Trans Res. 2020;13(3):431–450. doi: 10.1007/s12265-020-10042-3.
   PubMed Web of Science ®Google Scholar
• Porter C, Azam TU, Mohananey D, et al. Permissive cardiotoxicity: the clinical crucible of cardio. Oncology. JACC CardioOncol. 2022;4(3):302–312. doi: 10.1016/j.jaccao.2022.07.005.
   PubMedGoogle Scholar
• Porter C, Azam TU, Mohananey D, et al. Permissive cardiotoxicity: the clinical crucible of cardio-oncology. JACC Cardiooncology. 2022;4(3):302–312.
   PubMedGoogle Scholar
• Ramin C, Schaeffer ML, Zheng Z, et al. All-cause and cardiovascular disease mortality among breast cancer survivors in CLUE II, a long-standing community-based cohort. JNCI J Natl Cancer Inst. 2021;113(2):137–145. doi: 10.1093/jnci/djaa096.
   Web of Science ®Google Scholar
• Ell P, Martin JM, Cehic DA, et al. Cardiotoxicity of radiation therapy: mechanisms, management, and mitigation. Curr Treat Options Oncol. 2021;22(8):70.
   PubMed Web of Science ®Google Scholar
• Zhang X, Pawlikowski M, Olivo-Marston S, et al. Ten-year cardiovascular risk among cancer survivors: the national health and nutrition examination survey. PLoS ONE. 2021;16(3):e0247919. doi: 10.1371/journal.pone.0247919.
   PubMed Web of Science ®Google Scholar
• Emery J, Butow P, Lai-Kwon J, et al. Management of common clinical problems experienced by survivors of cancer. Lancet. 2022;399(10334):1537–1550. doi: 10.1016/S0140-6736(22)00242-2.
   PubMed Web of Science ®Google Scholar
• McMullen C, Clouser JM, Ada A, et al. Cardiovascular disease risk control in survivorship: the role and implementation of cardio-oncology services. Cardio Oncol. 2022;4(1):S17–S18. doi: 10.1016/j.jaccao.2022.01.006.
   Google Scholar
• Velusamy R, Nolan M, Murphy A, et al. Screening for coronary artery disease in cancer survivors: JACC: cardioOncology state-of-the-art review. Cardio Oncol. 2023;5(1):22–38.
   PubMedGoogle Scholar
• Rohrmann S, Witassek F, Erne P, et al. Treatment of patients with myocardial infarction depends on history of cancer. Eur Heart J Acute Cardiovasc Care. 2018;7(7):639–645. doi: 10.1177/2048872617729636.
   PubMed Web of Science ®Google Scholar
• Ngo DTM, Williams T, Horder S, et al. Factors associated with adverse cardiovascular events in cancer patients treated with bevacizumab. J Clin Med. 2020;9(8):2664.
   PubMed Web of Science ®Google Scholar
• Cehic DA, Sverdlov AL, Koczwara B, et al. The importance of primary care in cardio-oncology. Curr Treat Options Oncol. 2021;22(12):107.
   PubMed Web of Science ®Google Scholar
• Oliveria SA, Kohl HW, Trichopoulos D, et al. The association between cardiorespiratory fitness and prostate cancer. Med Sci Sports Exerc. 1996;28(1):97–104. doi: 10.1097/00005768-199601000-00020.
   PubMed Web of Science ®Google Scholar
• Laukkanen JA, Pukkala E, Rauramaa R, et al. Cardiorespiratory fitness, lifestyle factors and cancer risk and mortality in Finnish men. Eur J Cancer. 2010;46(2):355–363. doi: 10.1016/j.ejca.2009.07.013.
   PubMed Web of Science ®Google Scholar
• Mandsager K, Harb S, Cremer P, et al. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Netw Open. 2018;1(6):e183605. doi: 10.1001/jamanetworkopen.2018.3605.
   PubMed Web of Science ®Google Scholar
• Peel AB, Thomas SM, Dittus K, et al. Cardiorespiratory fitness in breast cancer patients: a call for normative values. J Am Heart Assoc. 2014;3(1):e000432.
   PubMed Web of Science ®Google Scholar
• Gilchrist SC, Barac A, Ades PA, et al. Cardio-Oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American heart association. Circulation. 2019;139(21):e997–e1012. doi: 10.1161/CIR.0000000000000679.
   PubMed Web of Science ®Google Scholar
• Chaosuwannakit N, D’Agostino RJr, Hamilton CA, et al. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol. 2010;28(1):166–172. doi: 10.1200/JCO.2009.23.8527.
   PubMed Web of Science ®Google Scholar
• Upshaw JN, Finkelman B, Hubbard RA, et al. Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy. JACC Cardiovasc Imaging. 2020;13(1):198–210. doi: 10.1016/j.jcmg.2019.07.018.
   PubMed Web of Science ®Google Scholar
• Reding KW, Cheng RK, Vasbinder A, et al. Lifestyle and cardiovascular risk factors associated with heart failure subtypes in postmenopausal breast cancer survivors. JACC CardioOncol. 2022;4(1):53–65. doi: 10.1016/j.jaccao.2022.01.099.
   PubMedGoogle Scholar
• La Gerche A, Howden EJ, Haykowsky MJ, et al. Heart failure with preserved ejection fraction as an exercise deficiency syndrome: JACC focus seminar 2/4. J Am Coll Cardiol. 2022;80(12):1177–1191. doi: 10.1016/j.jacc.2022.07.011.
   PubMed Web of Science ®Google Scholar
• Foulkes SJ, Howden EJ, Dillon HT, et al. Too little of a good thing: strong associations between cardiac size and fitness among women. JACC Cardiovasc Imag. 2023;16(6):768–778. doi: 10.1016/j.jcmg.2022.12.009.
   PubMed Web of Science ®Google Scholar
• Mishra SI, Scherer RW, Geigle PM, et al. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev. 2012;2012(8):Cd007566.
   PubMedGoogle Scholar
• Mishra SI, Scherer RW, Snyder C, et al. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev. 2012;2012(8):Cd008465.
   PubMedGoogle Scholar
• Foulkes SJ, Howden EJ, Haykowsky MJ, et al. Exercise for the prevention of anthracycline-induced functional disability and cardiac dysfunction: the BREXIT study | circulation. Circulation. 2023;147(7):532–545.
   PubMed Web of Science ®Google Scholar